News Headline Summary
Teva (TEVA) says superior patient outcomes compared with current studies support B-R combo as first line for lymphomas
- Reports significantly prolonged progression free survival.
- Reports significantly prolonged overall survival.
- Says B-R combo shows superior patient outcomes vs standard.
11 Dec 2012 - 12:33
Subscribe Now to RANsquawk
Click here for a 1 week free trial
RANsquawk provides audio news and commentary for over 15,000
professional traders and brokers worldwide. Services include:
Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
Teams of analysts covering equities, fixed income, FX and energy markets
Real-time scrolling news service with instant analysis
Daily and weekly pre-market research and calendars
Video updates covering near-term key risk events & primary trading themes
One-to-one chat with our expert analysts